IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v100y2011i2-3p196-202.html
   My bibliography  Save this article

Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan

Author

Listed:
  • Yeh, Hseng-Long
  • Huang, Li-Ying
  • Su, Syi
  • Yang, Ming-Chin
  • Wang, Ting-Chung

Abstract

Objectives National guidelines recommend angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) therapy for diabetic patients with hypertension and/or proteinuria to hinder renal disease progression. However, little is known about the adequacy of adherence to these guidelines in diabetic patients and about the predictors of such appropriate ACEIs or ARBs use. We sought to define the rates of ACEIs and ARBs use in a large population of patients with diabetic nephropathy (DN).Methods Using linked medical claims from the National Health Insurance Research Database, we studied a cohort of patients with DN. We used multivariate logistic regression to measure the predictors of usage of the agents studied.Results Of the 7159 DN patients studied, 5564 patients (77.7%) had hypertension. Of these, only 50.6% were administered ACEIs or ARBs during the quarter studied. In multivariate analyses, greater rates for usage of ACEIs or ARBs were found in patients with coronary artery disease or congestive heart failure.Conclusions Only 50% of the patients with DN received the recommended treatment with ACEIs or ARBs. This shortfall provides an opportunity for quality-improvement interventions that could provide beneficial clinical outcomes for these high-risk patients.

Suggested Citation

  • Yeh, Hseng-Long & Huang, Li-Ying & Su, Syi & Yang, Ming-Chin & Wang, Ting-Chung, 2011. "Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan," Health Policy, Elsevier, vol. 100(2-3), pages 196-202, May.
    • Handle: RePEc:eee:hepoli:v:100:y:2011:i:2-3:p:196-202
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(10)00342-8
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:100:y:2011:i:2-3:p:196-202. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.